No transcript available for this episode.
This episode examines the FDA clearance of Medtronic’s Stealth AXiS system for AI driven robotic spine surgery, Utah’s regulatory mitigation agreement for autonomous medication renewals covering one hundred ninety chronic conditions, and the Supreme Court’s certiorari grant in Hikma versus Amarin on induced infringement doctrine for skinny label generics. Additional coverage includes Federal Circuit rulings narrowing Orange Book patent listing criteria for combination drug delivery devices, and the Commissioner’s National Priority Voucher program structure and approval timelines. The briefing contextualizes these developments within evolving frameworks for algorithmic governance, patent liability, and expedited regulatory pathways.